Cardiff Scintigraphics / i2c Pharmaceutical Services (CSL/i2c) Appoints Dr John Pritchard as the new Chairman

Cardiff, UK, Press Release 26th June 2024

Cardiff Scintigraphics has appointed John Pritchard as the new Chairman of the Board of Directors with effect from 27th June 2024. John will be succeeding Dr David Owen who will be stepping down as a member of the Board. We would like to thank David for his support and Chairmanship over the past 5 years and he will remain as a consultant for the company to support the next stage of growth.

John is an internationally recognised expert and leader in Inhalation Product Development, with experience across a range of companies including GSK, 3M, AZ and Phillips Healthcare. He has published extensively in the field of inhaled drug delivery and received the prestigious Charles G Thiel award at RDD in 2018. John has expressed his enthusiasm to chair CSL/i2c saying “I’m looking forward to the challenge of stepping into David’s role at what I think will be very exciting times for the company. The Board combines well over 100 years’ experience in the development of respiratory products and so I will have tremendous support from the team”

“John brings a wealth of experience at executive level to CSL/i2c and will play a strong role in the next phase of the company’s expansion and he has the unanimous support of the Board” said Andrew Brown, CEO of CSL/i2c. Founded in 1992, CSL/i2c is a leading contract research centre of excellence for inhaler development and testing, enabling the transitions from inception of concept and research data, fast-tracking through to clinical trials. For more information, please visit the company’s websites or, or contact or phone +44 29 2075 7865.